Table 1.
Baseline characteristics.
| E/M hybrid-predominant (n = 34) | Non-E/M hybrid- predominant (n = 25) | χ2 | P value | |
|---|---|---|---|---|
| Age (years) | ||||
| Median (range) | 46 (17–63) | 46 (29–71) | ||
| ≦45 | 15 (44.1%) | 10 (40.0%) | 0.100 | 0.752 |
| >45 | 19 (55.9%) | 15 (60.0%) | ||
| Sex | ||||
| Male | 30 (88.2%) | 19 (76.0%) | 0.786 | 0.375 |
| Female | 4 (11.8%) | 6 (24.0%) | ||
| Ethnicity | ||||
| Asian | 34 (100%) | 25 (100%) | ||
| Histology | ||||
| Non-keratinizing squamous cell carcinoma | 34 (100%) | 25 (100%) | ||
| T category | ||||
| T1-2 | 4 (11.8%) | 8 (32.0%) | 2.499 | 0.114 |
| T3-4 | 30 (88.2%) | 17 (68.0%) | ||
| N category | ||||
| N0-1 | 21 (61.8%) | 14 (56.0%) | 0.198 | 0.656 |
| N2-3 | 13 (38.2%) | 11 (44.0%) | ||
| Stage | ||||
| III | 18 (52.9%) | 18 (72.0%) | 2.200 | 0.138 |
| IV | 16 (47.1%) | 7 (28.0%) | ||
| Pretreatment EBV DNA test | ||||
| Positive | 17 (50.0%) | 14 (56.0%) | 0.208 | 0.648 |
| Negative | 17 (50.0%) | 11 (44.0%) | ||
Data are presented as n (%) or median (range). χ2 was calculated by chi-square test with or without continuous calibration, or with Fisher’s exact test.